Lymphoma
An Introduction to Lymphoma
Lymphoma is one of the ten most common malignancies worldwide. While some lymphomas are curable, the treatment of relapsed and refractory disease remains a substantial challenge. Recent advances have led to the development of a number of new treatment strategies, including novel antibodies targeting surface antigens, small molecular inhibitors targeting oncogenic signalling pathways and tumour suppressors, and immune checkpoint inhibitors. Chimeric antigen receptor (CAR) T-cells offer the potential for personalised therapy. The emergence of so many new therapeutic options have raised challenges in terms of optimal sequencing and combined approaches, and have highlighted the need for biomarkers to predict therapeutic response.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Marginal zone lymphoma subtypes Marginal zone lymphoma (MZL) is an indolent non-Hodgkin lymphoma (NHL) that accounts for 5.0%–10.0% of NHLs.1 There are three subtypes of MZL: extranodal (including mucosa-associated lymphoid tissue [MALT]), splenic and nodal.1 Extranodal MZL (EMZL) is the most ...
B-cell signalling pathways are critical regulators of B-cell development, expansion, and survival and function via various mediators, including Src family kinases (SFKs), spleen tyrosine kinase, Bruton’s tyrosine kinase (BTK) and phosphatidylinositol 3 kinase (PI3K) (Figure 1).1,2 BTK, a member of ...
The addition of rituximab to chemotherapy provides an overall survival benefit in aggressive lymphomas,1 whereas for indolent lymphoma subtypes this addition has resulted in improvements in progression-free survival.2 For more than two decades, immunotherapy with monoclonal ‘naked’ antibodies targeting CD20 ...
Allogeneic haematopoietic stem cell transplant (allo-HSCT) remains a potential curative therapeutic option for patients with refractory/relapsed Hodgkin lymphoma (HL) in whom an autologous peripheral blood stem-cell transplantation (PBSCT) has failed. This is explained by the additional benefit of a ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
